News & Updates
Filter by Specialty:
COVID-19 vaccine boosters effective against Omicron in people with substance use disorder
COVID-19 vaccine boosters provide protection against Omicron infection and related hospitalization among people with substance use disorder, researchers from the University of Hong Kong have reported.
COVID-19 vaccine boosters effective against Omicron in people with substance use disorder
29 May 2023
Long COVID: Gut microbiome modulation alleviates neuropsychiatric and GI symptoms
Modulation of gut microbiome using the SIM01 synbiotic formula significantly improves neuropsychiatric and gastrointestinal (GI) symptoms of long COVID, according to results of the randomized, triple-blind, placebo-controlled RECOVERY study conducted by researchers from the Chinese University of Hong Kong (CUHK).
Long COVID: Gut microbiome modulation alleviates neuropsychiatric and GI symptoms
29 May 2023
In-utero exposure to poor air quality a risk factor for childhood ADHD
Children born to mothers who were exposed to polluted air while pregnant are at increased risk of childhood attention-deficit hyperactivity disorder (ADHD), according to a study presented at PAS 2023.
In-utero exposure to poor air quality a risk factor for childhood ADHD
20 May 2023
Motivational interviewing plus CBT eases negative symptoms in schizophrenia
Motivational interviewing (MI) in combination with cognitive behavioural therapy (CBT) improves negative symptoms in patients with schizophrenia, reports a study. These symptoms are initially thought of as resistant to any intervention.
Motivational interviewing plus CBT eases negative symptoms in schizophrenia
11 May 2023
Can antipsychotic monotherapy prevent hospitalizations in schizophrenia?
A recent study has shown that antipsychotic monotherapy does not reduce the risk of hospitalization for severe physical health problems when compared with polypharmacy in patients with schizophrenia.
Can antipsychotic monotherapy prevent hospitalizations in schizophrenia?
10 May 2023
Psilocybin shows promise in relieving depression in cancer patients
The 5-HT2A receptor agonist psilocybin, when taken under medical supervision, may offer a promising approach to treatment of major depressive disorder (MDD) in cancer patients, results of a small phase II study suggest.